US Broker Ratings

SI-BONE, Inc. (SIBN) Stock Analysis: A 47% Upside Potential in the Healthcare Sector

SI-BONE, Inc. (NASDAQ: SIBN), a prominent player in the healthcare sector, is drawing significant attention from investors due to its innovative approach to addressing musculoskeletal disorders. With a focus on..

iRadimed Corporation (IRMD) Stock Analysis: Exploring a 23.59% Potential Upside in the Healthcare Sector

Investors with a keen eye on the medical devices industry should not overlook iRadimed Corporation (NASDAQ: IRMD). This healthcare sector player, headquartered in Winter Springs, Florida, is gaining traction with..

Iovance Biotherapeutics (IOVA) Stock Analysis: Exploring a Potential 357% Upside in the Biotech Sector

Investors with an appetite for high-risk, high-reward opportunities might find Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) an intriguing prospect. This biotechnology company, valued at approximately $781.41 million, operates within the healthcare..

Pharvaris N.V. (PHVS): Analyst Consensus Signals a 43.64% Upside for This Biotech Stock

Pharvaris N.V. (NASDAQ: PHVS), a Switzerland-based biotechnology company, prominently stands out in the healthcare sector with its focus on developing innovative treatments for rare diseases. With a market cap of..

Intellia Therapeutics (NTLA) Stock Analysis: Exploring a Potential 215% Upside in Gene Editing

Intellia Therapeutics, Inc. (NASDAQ: NTLA) stands at the forefront of the healthcare sector, particularly within the dynamic field of biotechnology. With a market capitalization of $1.23 billion, this Cambridge, Massachusetts-based..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Biotech Powerhouse with 219% Potential Upside

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical stage biotechnology company, is making waves in the healthcare sector with its innovative therapies targeting inflammatory bowel diseases (IBD) such as ulcerative colitis..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: 25% Upside Potential Amidst Healthcare Sector Expansion

Investors seeking exposure to the healthcare sector, particularly in the diagnostics and research industry, may find Fulgent Genetics, Inc. (NASDAQ: FLGT) an intriguing opportunity. With a market capitalization of approximately..

CareDx, Inc. (CDNA) Investor Outlook: Unpacking a 147.97% Potential Upside

CareDx, Inc. (NASDAQ: CDNA), a prominent player in the healthcare sector specializing in diagnostics and research, is drawing significant attention from investors with its substantial potential upside of 147.97%. As..

Trevi Therapeutics, Inc. (TRVI) Investor Outlook: 210% Potential Upside Sparks Interest

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is capturing attention in the biotech sector with its significant potential upside, as highlighted by recent analyst ratings. Based in New Haven, Connecticut, Trevi Therapeutics..

HealthStream, Inc. (HSTM) Stock Analysis: Exploring a 27.59% Potential Upside for Investors

HealthStream, Inc. (NASDAQ: HSTM) is capturing the attention of investors with its promising potential upside of 27.59%, according to the latest analyst consensus. As a key player in the healthcare..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Unpacking a Potential 225% Upside

Vir Biotechnology, Inc. (NASDAQ: VIR) is a compelling case for investors with a keen eye on the biotechnology sector. Despite facing significant revenue challenges, the company presents an intriguing potential..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Evaluating a Promising 28.72% Potential Upside

In the ever-evolving world of biotechnology, LENZ Therapeutics, Inc. (NASDAQ: LENZ) stands out as a compelling story for investors. With a market capitalization of $973.01 million, this Solana Beach, California-based..

Beta Bionics, Inc. (BBNX) Stock Analysis: Unlocking a 78.93% Potential Upside in the Medical Device Sector

Beta Bionics, Inc. (NASDAQ: BBNX), a promising player in the healthcare sector, is capturing investor attention with a significant potential upside of 78.93%. The company’s pioneering work in the medical..

uniQure N.V. (QURE) Stock Analysis: Unveiling a 136.80% Upside Potential in Gene Therapy Innovations

Investors interested in the biotechnology sector are increasingly turning their attention to uniQure N.V. (NASDAQ: QURE), a trailblazer in the development of gene therapies for rare diseases. With a market..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Navigating a 32% Revenue Growth Amidst Valuation Concerns

Phibro Animal Health Corporation (NASDAQ: PAHC), a prominent player in the healthcare sector, specializes in manufacturing and marketing animal health products, mineral nutrition, and performance products across the globe. With..

Ardelyx, Inc. (ARDX) Stock Analysis: Exploring a Potential 137% Upside in the Biotech Space

Ardelyx, Inc. (NASDAQ: ARDX) is carving a niche in the biotechnology sector with its innovative therapies aimed at addressing unmet medical needs, and its financial metrics suggest a compelling opportunity..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a 27.87% Potential Upside in Pain Management Innovation

Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a dynamic player in the healthcare sector, specifically in the specialty and generic drug manufacturing industry, has been catching the eye of investors seeking potential..

InMode Ltd. (INMD) Stock Analysis: Uncovering a 20% Potential Upside in the Medical Devices Sector

In the dynamic world of medical devices, InMode Ltd. (NASDAQ: INMD) stands out as a company that has carved a niche in the aesthetic healthcare market. Based in Israel, InMode..

Geron Corporation (GERN) Stock Analysis: Exploring a 185.85% Potential Upside in the Biotech Sector

Geron Corporation (NASDAQ: GERN) is capturing investor attention with a staggering potential upside of 185.85%, according to analyst estimates. This commercial-stage biopharmaceutical company, headquartered in Foster City, California, focuses on..

Arcus Biosciences (RCUS) Stock Analysis: Exploring a 199% Potential Upside in Biotechnology

Arcus Biosciences, Inc. (NASDAQ: RCUS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to cancer therapies. Based in Hayward, California, Arcus is focused..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds